The role of blood tumor markers in monitoring response in advanced breast cancer is established in endocrine therapy and standard chemotherapy. This study examines marker levels in patients receiving new chemotherapy regimens. Thirty patients were recruited into two multicenter trials in which docetaxel-based regimens were used in 15 patients. The other 15 received doxorubicin-based regimens. Biochemical response calculated from a score using CA15.3, CEA and ESR was compared with UICC response. Marker changes at 2, 4 and 5 months correlated with UICC response at 3, 41/2 and 6 months, respectively (p < 0.03). Eleven patients achieved both clinical/radiological and biochemical response at the end of treatment; markers had not yet returned to below cutoffs in seven, suggesting a possible advantage to continue chemotherapy. No patient showed a biochemical response whilst judged clinically/radiologically progressive. Nineteen patients had progressed either clinically/radiologically or biochemically at six months; of these, eight showed progression assessed earlier by markers so that a median of four cycles of chemotherapy could have been saved. Measurements of serum c-erbB2 showed a correlation with tissue c-erbB2 staining in the primary tumor (p < 0.003). Among the patients with positive tissue staining, sequential changes in serum c-erbB2 completely paralleled initial response. (Int J Biol Markers, 2000; 15: 203-9)
INTRODUCTION
Blood tumor markers of breast cancer have been known for decades. In contrast to markers in tumor tissue, blood tumor markers reflect a dynamic situation and their measurements can be repeated as required.
The use of blood tumor markers in breast cancer patients has been established in symptomatic metastatic disease. A combination of several markers gives a high sensitivity and specificity for the diagnosis of metastatic breast cancer. Monitoring of therapy with markers has been shown to be superior to monitoring by conventional criteria laid down by the International Union Against Cancer (UICC) (1) . The imaging tests according to UICC criteria reflect structural change -a late event because it depends on at least one metastasis reaching a significant size. Changes in blood tumor markers appear to reflect the total tumor burden which may be measurable from the summation of numerous subclinical metastases.
On retrospective and prospective analyses we have previously demonstrated the usefulness of a biochemical index score, derived from a combination of three serum tumor markers, i.e. MUC1 mucin measured as CA15.3, carcinoembryonic antigen (CEA) and erythrocyte sedimentation rate (ESR), in the monitoring of therapeutic response in endocrine therapy as well as chemotherapy, e.g. standard regimens using cyclophosphamide, methotrexate and 5-fluorouracil (CMF), mitozantrone and anthracycline-based regimens (2) (3) (4) (5) . With advances in medical oncology, increasing varieties of cytotoxic therapy including taxanes are nowadays being used in the treatment of advanced breast cancer. On the other hand, the potential role of measurement of the c-erbB2 extracellular domain in the serum in predicting response to, and thus monitoring chemotherapy has recently gained attention (6) . This is a further paper examining the role of the blood tumor markers in directing cytotoxic therapy regimens including taxanes. In addition to the use of the previously devised biochemical index score, the role of serum c-erbB2 was investigated.
MATERIALS AND METHODS
During the period from April 1995 to February 1998, 30 patients (15 in each trial) with advanced breast cancer treated in the Nottingham Breast Unit were recruited into two multicenter phase III randomized chemotherapy trials.
The first trial aimed to compare docetaxel (100 mg/m 2 three-weekly for a maximum of seven cycles) to doxorubicin (75 mg/m 2 three-weekly for a maximum of seven cycles) in patients with metastatic breast cancer who had failed an alkylating agent containing regimen. The second trial compared docetaxel (75 mg/m 2 threeweekly) in combination with doxorubicin (50 mg/m 2 three-weekly) to doxorubicin (60 mg/m 2 three-weekly) in combination with cyclophosphamide (600 mg/m 2 threeweekly) (all for a maximum of eight cycles) as first-line chemotherapy for metastatic breast cancer. For both trials, all patients were required to have measurable (bi-or uni-dimensionally measurable lesion) and/or assessable disease. Patients with sclerotic bone metastases and/or lymphangitis carcinomatosa and/or ascites and/or pleural effusion as the only manifestation of disease were not eligible. Patients were also excluded if they had a past or current history of neoplasms other than breast carcinoma, except for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix. All 30 patients in this study received a maximum number of cycles of treatment unless they had clinical/radiological disease progression prior to its completion or adverse events had developed as a result of the treatment or concomitant illnesses.
Assessment of response and direction of therapy
Assessment of therapeutic response was carried out using the UICC criteria after every two cycles as required by the trials. Therapy was directed by UICC criteria -change of therapy was instituted only at the time of disease progression, otherwise patients would receive the maximum number of cycles of the regimens. For the purpose of analysis, response categories were grouped into 'non-progression' (complete response, partial response and stable disease) and 'progression' as reported (7) (8) (9) . In fact, discontinuation of therapy was required as per study protocols at the time of disease progression as mentioned above.
Serial measurements of three serum tumor markers (CA15.3, CEA and ESR) were carried out monthly after each cycle. Remaining serum from all samples was stored at -20ºC for c-erbB2 assays which were carried out retrospectively for the current study.
Biochemical index score
A biochemical index score comprising the three markers (CA15.3, CEA and ESR) was calculated in the same manner as previously described (Table I) (2, 10) .
Serum c-erbB2 measurement
C-erbB2 assays were carried out using the Bayer Immuno 1TM System, HER-2/neu (H2N) (Bayer, USA), which was a sandwich immunoassay. Two c-erbB2 antibody conjugates were reacted with patient sample and incubated on the system at 37°C. The monoclonal Im-munoMagnetic Particle (mIMPTM) reagent was added and a second incubation occurred during which the antibody complex was bound. The mIMP/antibody complex was then washed and the para-nitrophenyl phosphate (pNPP) substrate was added. The alkaline phosphatase in the antibody conjugate reacted with the pNPP to form para-nitrophenoxide and phosphate. The absorbance as a result of the formation of para-nitrophenoxide was monitored at 405 nm and 450 nm. The upper limit of normal was taken at 20 ng/mL.
Tissue c-erbB2 measurement
For the purpose of correlation with serum c-erbB2 measurements, tumor tissues obtained from the primary breast cancer when these patients had their initial surgery were retrieved and stained for c-erbB2 overexpression.
Immunohistochemistry was performed by a standard streptavidin-biotin complex (StreptABComplex) technique on formalin-fixed, paraffin wax-embedded tissue. Briefly, the sections were de-waxed in xylene and taken to alcohol. Endogenous peroxidase was blocked with hydrogen peroxide in methanol and the section was subsequently washed in tap water and rinsed in tris buffered saline (TBS). Non-specific binding sites were blocked with normal swine serum for 10 minutes, which was then drained and the primary antibody applied. After further washes in TBS the biotinylated secondary antibody was applied for 30 minutes. After a further wash in TBS the StreptABComplex was applied. After a further wash in TBS the label was developed using diamenobenzadine and enhanced with copper sulphate solution. After a further wash in tap water the sections were counter-stained in hematoxylin and mounted. Immunohistochemical staining was assessed by a consultant breast pathologist. Membrane staining with c-erbB2 antibody only was recorded and scored as negative, weak and focal, moderate and extensive or strongly positive and extensive. For analysis in the present study only those cases showing extensive (moderate or strong) staining were regarded as positive for c-erbB2 oncoprotein.
Statistical methods
Statistical analysis was carried out using the standardized biomedical computer program SPSS for Windows (SPSS UK LTD). Comparison of frequencies of integers between variables was done by chi-squared test with Yates correction where appropriate. Statistically significant difference was defined by p < 0.05.
RESULTS
Almost one third of the patients in this study had received various kinds of systemic therapies prior to inclusion into the trials (Table II) . The liver was the most common site of metastasis in these patients (Table III) . A mean of 4.5 cycles of chemotherapy (range: 1-8 cycles) were given. Withdrawal of therapy (because of disease progression) gave 30, 23, 20 and 17 patients, respectively, available for analysis at 1 1/2, 3, 4 1/2 and 6 months.
Biochemical index score
Three patients were biochemically unassessable throughout the whole period of study because all the three markers were below the cutoff levels. All three patients remained in remission throughout the same period with partial response achieved and maintained after the second cycle of chemotherapy. We have previously reported three similar patients in a multicenter study of serum tumor markers for monitoring therapeutic response in patients with metastatic breast cancer (5) . Their markers remained within the normal levels throughout, while markers for other patients which started off with normal values rose on disease progression.
For the 15 patients receiving docetaxel containing regimens, either alone or in combination with doxorubicin, marker changes at two and seven months correlated significantly with UICC-assessed response at three and six months (Table IV) . There was complete correlation be-tween biochemical response at two months and UICC-assessed response at three months (Table IVa) . The patient who progressed biochemically at five months while being assessed as non-progression by UICC criteria at six months had clinical/radiological progression at seven months (Table IVb) .
When all 30 patients were included in the analysis, marker changes at two, four and five months correlated significantly with UICC, assessed response at 3, 4 1/2 and six months, respectively (Table V) . For the four patients who had biochemical progression whilst assessed as non-progression by UICC criteria (Table Va-c), all had progressed clinically/radiologically after a median of 1.5 months (range: 1-3 months). The patient who progressed at six months according to UICC criteria whilst judged as having a biochemical response at five months had progressed biochemically at six months (Table Vc) . Eleven patients achieved both clinical and biochemical response at the end of the treatment; tumor markers had not yet returned to below the cutoff values in seven of them. Nineteen patients had pro-gressed either clinically/radiologically or biochemically at six months; of these eight showed progression earlier assessed by tumor markers, so that one to five cycles (median = four cycles) of chemotherapy could have been saved.
Serum c-erbB2 measurement
Twenty patients had both tissue and pre-chemotherapy serum c-erbB2 samples available for analysis. There was a strong correlation between positive tissue c-erbB2 staining and increased serum c-erbB2 level before chemotherapy, i.e. at the time of metastases (Table VI) . Elevation of serum c-erbB2 was found in 11/12 (92%) patients with tumor tissue which stained positive for c-erbB2, while only 1/9 (11%) patients with negative tissue staining had increased levels of serum c-erbB2. Eleven of the 12 patients with positive tissue c-erbB2 staining had elevated serum c-erbB2 before chemotherapy and their initial measurements completely paralleled the initial response. The remaining one patient had normal serum c-erbB2 throughout and the patient remained in remission (Table VII) . The mean value of serum c-erbB2 in these 12 patients was 290 ng/mL (range: 12-1010 ng/mL). The single patient with negative tissue staining but increased serum c-erbB2 only had a marginal elevation (25 ng/mL) above the cutoff. In other words, among all patients with positive tissue c-erbB2 staining, there was complete correlation between serum c-erbB2 measurements and initial response. Whenever there was a decreasing trend (at least 20% fall from the pre-treatment value was seen) in serum c-erbB2 for a responder, it was almost evident immediately at one month after commencing treatment (the plot for a typical patient is shown in Figure 1 ). For the patient with an initial complete response, there was a transient elevation of serum c-erbB2 in the first month before a rapid fall was seen ( Figure 2 ). For patients who showed initial disease remission, there were inadequate sequential serum samples for further correlation between serum c-erbB2 and later disease progression.
Addition of serum c-erbB2 measurement to the biochemical index score
When the 12 patients with positive tissue c-erbB2 staining were considered, at one month after commencing chemotherapy, the subsequent UICC response could be predicted by serum c-erbB2 alone in 10 patients and by the biochemical index score alone in seven patients. All patients whose response could be predicted by the score had their response also predicted by serum c-erbB2. Therefore combining the index with serum c-erbB2 did not improve the predictability in this small number of patients. As mentioned above, there were inadequate serum samples for further evaluation at the time of later disease progression. 
DISCUSSION
The use of blood tumor markers in monitoring the therapeutic response in advanced breast cancer has been shown to be superior to the conventional clinical/radiological assessment based on UICC criteria in both endocrine and standard cytotoxic therapy, both retrospectively and prospectively, according to data from our Unit as well as from a multicenter study involving 127 patients from 11 centers in Europe (2, 4, 11) . Biochemical assessment is more reliable, objective, reproducible and cost-effective. Biochemical indication of response or progression is seen ahead of clinical/radiological response or progression, thus allowing more effective palliation, which is especially important in patients with advanced breast cancer. Early discontinuation of ineffective therapy, early change of treatment for non-responders, and further continuation of effective treatment are thus feasible.
Over 90% of patients are biochemically assessable and the sensitivity of the assessment is above 90% (2, 4, 5) . Biochemical assessment also provides a method for assessing response in disease unassessable by UICC criteria, e.g. sclerotic bone metastases. It is the only quantitative method of assessing non-measurable but assessable disease, e.g. pleural effusion. All these account for 10-40% of all patients (11) (12) (13) (14) . In the recently published British Association of Surgical Oncology (BASO) Guidelines for the Management of Metastatic Bone Disease in Breast Cancer in the United Kingdom, blood tumor marker measurement is also recommended as a method of monitoring therapy (15) . Biochemical assessment may result in at least 50% cost-savings when compared with assessment by clinical/radiological criteria, which often require expensive imaging techniques such as CT or MRI scans (16) .
The present study is small but has the advantage of having all the stringent recruitment and assessment criteria required in the two prospective trials, with all patients entered having disease assessable by clinical and/or radiological criteria, with accurate assessment and follow-up data. This paper adds to the literature on marker measured response and is the first paper which primarily addresses the role of blood tumor markers in directing docetaxel containing regimens.
The results again confirm the superior role of biochemical assessment over conventional assessment in the monitoring of chemotherapy in advanced breast cancer. Progression may be judged ahead of conventional assessment. Significant cost-savings are therefore achievable by directing the application of expensive cytotoxics by tumor markers. A median of four cycles of chemotherapy could have been saved in the eight patients who showed progression earlier if the therapy had been directed by tumor markers (a saving of £1,600/cycle for docetaxel). In addition, patients themselves benefit from earlier discontinuation of treatment. They do not have to suffer prolongation of side-effects from an ineffective treatment and possibly effective therapies may be instituted.
Although three patients had all marker levels below the cutoff values, all of them remained in remission throughout the study. Therefore it appears, as demonstrated in a recent multicenter study, that all patients, even those without elevated marker measurements on baseline tests, can be entered into a marker-directed therapy program (5) .
Eleven patients achieved both clinical/radiological and biochemical response at the end of the treatment; tumor markers had not yet returned to below the cutoff values in seven of them, suggesting the possibility of continuing cytotoxic therapy. The benefit of continuing cytotoxic therapy according to marker level has already been shown in other regimens such as CMF; with better duration of remission and survival, and possible improved quality of life (4, 17) . The present study again suggests such benefit in the use of tumor markers in new 
Months
Months Serum c-erbB2 (ng/ml) Serum c-erbB2 (ng/ml) regimens with taxanes, for instance in the treatment of advanced breast cancer. Part of the extracellular domain of the c-erbB2 receptor has been detected in the circulation of some patients with breast cancer. Literature review shows that elevation of serum c-erbB2 is detected in 80% of patients with tumors which overexpress c-erbB2 compared to 3.3% of those which do not overexpress the oncoprotein. Correlation between c-erbB2 expression in tissue and low estrogen receptor status seemed to be found when serum c-erbB2 was elevated. It would appear that measurement of the c-erbB2 extracellular domain in the serum might be useful in monitoring for tumor recurrence and in predicting resistance to endocrine therapy. However, it has not yet been shown to be promising in predicting response to chemotherapy (6, 18) . With a limited number of patients in this study, correlation between tissue c-erbB2 staining and elevated serum c-erbB2 has been demonstrated. The sequential changes in serum c-erbB2 levels also paralleled remarkably the initial response to chemotherapy. The addition of serum c-erbB2 measurement to the validated biochemical index score also seems to increase the predictive power of the initial therapeutic response. A transient rise of serum c-erbB2 level was seen in the single patient with a complete response. Whether this could represent a spike phenomenon as seen in conventional blood tumor markers such as CA15.3 in responders remains to be elucidated. If this is the case, particular caution needs to be taken when interpreting results of serum measurements (19) .
Further studies involving larger numbers of patients with prolonged longitudinal measurements will be required to validate the precise role of serum c-erbB2 in monitoring patients on chemotherapy for advanced breast cancer, including its capacity in predicting disease progression which could not be demonstrated in the present study owing to the lack of serum samples. It appears that the use of serum c-erbB2 measurements may be promising in patients with tumors which overexpressed c-erbB2. It is likely that its future use will complement the currently available tumor markers such as CA15.3 in this group of patients.
